ULTRA-TECHNEKOW V4 Drug Patent Profile

When do Ultra-technekow V4 patents expire, and when can generic versions of Ultra-technekow V4 launch?

Ultra-technekow V4 is a drug marketed by Curium and is included in one NDA.

The generic ingredient in ULTRA-TECHNEKOW V4 is technetium tc-99m sodium pertechnetate generator. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the technetium tc-99m sodium pertechnetate generator profile page.

Summary for ULTRA-TECHNEKOW V4

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ULTRA-TECHNEKOW V4

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Curium	ULTRA-TECHNEKOW V4	technetium tc-99m sodium pertechnetate generator	SOLUTION;INTRAVENOUS	017243-003	Feb 18, 2014		RX	Yes	Yes
Curium	ULTRA-TECHNEKOW V4	technetium tc-99m sodium pertechnetate generator	SOLUTION;INTRAVENOUS	017243-002	Approved Prior to Jan 1, 1982		DISCN	No	No

ULTRA-TECHNEKOW V4: Investment Scenario and Fundamentals Analysis

Last updated: April 24, 2026

No credible, citable patent, regulatory, clinical, or market data links the named product “ULTRA-TECHNEKOW V4” to a specific active pharmaceutical ingredient (API), marketing authorization, investigational pipeline candidate, or inventor/assignee portfolio. As a result, a complete investment scenario and fundamentals analysis cannot be produced without fabricating facts.

What is ULTRA-TECHNEKOW V4 in regulatory and patent terms?

• No verifiable regulatory identifier (e.g., FDA NDA/BLA/ANDA, EMA marketing authorization number, or international nonproprietary name mapping) is available for “ULTRA-TECHNEKOW V4.”
• No verifiable patent family, applicant/assignee, priority claim, or legal status record is available for the named product string.

What are the investment fundamentals (clinical, regulatory, exclusivity) for ULTRA-TECHNEKOW V4?

• Clinical: No citable trial registrations, endpoints, or phase information can be matched to “ULTRA-TECHNEKOW V4.”
• Regulatory: No citable approval status, labeling, launch dates, or jurisdictional timelines can be matched to “ULTRA-TECHNEKOW V4.”
• Exclusivity and barriers: No citable patent expiry, SPC/paediatric extensions, Orphan status, exclusivity grants, or reference product dependency can be matched to “ULTRA-TECHNEKOW V4.”

What is the market and commercial baseline for ULTRA-TECHNEKOW V4?

• No citable claims for indication, patient population, pricing, payer coverage, reimbursement codes, competitor landscape, or forecast demand can be tied to “ULTRA-TECHNEKOW V4.”

What is the patent-backed investment profile for ULTRA-TECHNEKOW V4?

• No citable patent clusters (composition of matter, formulation, process, method of treatment, use claims), no prosecution/legal status timeline, and no freedom-to-operate (FTO) indicators can be established from reliable sources for “ULTRA-TECHNEKOW V4.”

Key Takeaways

• “ULTRA-TECHNEKOW V4” is not identifiable to a specific, citable pharmaceutical product, API, or patent/regulatory asset in the available record space.
• Without a traceable mapping to regulatory status and patent families, investment scenario construction would require unsupported assumptions.

FAQs

1. Can you analyze ULTRA-TECHNEKOW V4’s patent expiry and exclusivity?
   Not with facts because no traceable patent or exclusivity record can be linked to the product name.

2. Can you estimate commercial opportunity (peak sales, pricing, patient pool)?
   Not with facts because indication, API, and authorization details cannot be matched to the product name.

3. Can you assess clinical risk (phase, endpoints, success probability)?
   Not with facts because trial registrations and endpoints cannot be tied to the product name.

4. Can you build an investment case (bull/base/bear) for ULTRA-TECHNEKOW V4?
   Not with facts because the asset (drug identity and governing IP/regulatory bundle) is not confirmable.

5. Can you evaluate competitive landscape and FTO pressure?
   Not with facts because the product identity and claim-relevant patent family are not traceable.

---

References

[1] No citable sources are available for “ULTRA-TECHNEKOW V4” that identify an API, regulatory marketing authorization, clinical trial registration, or patent family.